Instil Bio, Inc.
A Dallas biotech firm working on a personal kind of cancer immunotherapy: it takes a patient's own immune cells that have already wandered into a tumor, multiplies them into an army in the lab, and infuses them back to hunt down the cancer. Founded in 2018, the company also developed a CoStAR platform meant to give those engineered cells an extra "on" switch when they meet a tumor. Its name plays on "instil" — boosting the body's own natural immune response to fight disease.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 13G/APassive | 9.5% | 645.6K | Feb 9, 2026 |
| Vivo Capital IX, LLC | 13G/APassive | 4.5% | 292.7K | Aug 12, 2025 |
| Vivo Capital Fund IX, L.P. | 13G/APassive | 4.5% | 292.7K | Aug 12, 2025 |
| Aaron I. Davis | 13G/APassive | 1.2% | 80.1K | May 15, 2025 |
| Boxer Capital Management, LLC | 13G/APassive | 1.2% | 80.1K | May 15, 2025 |
| Boxer Asset Management Inc. | 13G/APassive | 0% | 0 | May 15, 2025 |
| Joe Lewis | 13G/APassive | 0% | 0 | May 15, 2025 |
| MVA Investors, LLC | 13G/APassive | 0% | 0 | May 15, 2025 |
| Boxer Capital, LLC | 13G/APassive | 0% | 0 | May 15, 2025 |
| Perceptive Advisors LLC | 13G/APassive | 0% | 0 | May 15, 2025 |